Coherus Biosciences expects to launch a pegfilgrastim biosimilar in 2018. Other biosimilars in its pipeline include those referencing Lucentis, or ranibizumab; Eylea, or aflibercept; Humira, or adalimumab; and Enbrel, or etanercept.